Literature DB >> 29428542

Quantification of microwave-induced amorphization of celecoxib in PVP tablets using transmission Raman spectroscopy.

Magnus Edinger1, Matthias Manne Knopp2, Hugo Kerdoncuff3, Jukka Rantanen1, Thomas Rades1, Korbinian Löbmann1.   

Abstract

In this study, the influence of drug load on the microwave-induced amorphization of celecoxib (CCX) in polyvinylpyrrolidone (PVP) tablets was investigated using quantitative transmission Raman spectroscopy. A design of experiments (DoE) setup was applied for developing the quantitative model using two factors: drug load (10, 30, and 50% w/w) and amorphous fraction (0, 25, 50, 75 and 100%). The data was modeled using partial least-squares (PLS) regression and resulted in a robust model with a root mean-square error of prediction of 2.5%. The PLS model was used to study the amorphization kinetics of CCX-PVP tablets with different drug content (10, 20, 30, 40 and 50% w/w). For this purpose, transition Raman spectra were collected in 60 s intervals over a total microwave time of 10 min with an energy input of 1000 W. Using the quantitative model it was possible to measure the amorphous fraction of the tablets and follow the amorphization as a function of microwaving time. The relative amorphous fraction of CCX increased with increasing microwaving time and decreasing drug load, hence 90 ± 7% of the drug was amorphized in the tablets with 10% drug load whereas only 31 ± 7% of the drug was amorphized in the 50% CCX tablets. It is suggested that the degree of amorphization depends on drug loading. The likelihood of drug particles being in direct contact with the polymer PVP is a requirement for the dissolution of the drug into the polymer upon microwaving, and this is reduced with increasing drug load. This was further supported by polarized light microscopy that revealed evidence of crystalline particles and clusters in all the microwaved tablets.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amorphization; Amorphous solid dispersion; Glass solution; Microwave radiation; Polymer; Transmission Raman spectroscopy

Mesh:

Substances:

Year:  2018        PMID: 29428542     DOI: 10.1016/j.ejps.2018.02.012

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

1.  Hyperthermia-Induced In Situ Drug Amorphization by Superparamagnetic Nanoparticles in Oral Dosage Forms.

Authors:  Shaquib Rahman Ansari; Nele-Johanna Hempel; Shno Asad; Peter Svedlindh; Christel A S Bergström; Korbinian Löbmann; Alexandra Teleki
Journal:  ACS Appl Mater Interfaces       Date:  2022-04-22       Impact factor: 10.383

2.  Convection-Induced vs. Microwave Radiation-Induced in situ Drug Amorphization.

Authors:  Nele-Johanna Hempel; Matthias M Knopp; Ragna Berthelsen; Korbinian Löbmann
Journal:  Molecules       Date:  2020-02-27       Impact factor: 4.411

3.  Determination of the physical state of a drug in amorphous solid dispersions using artificial neural networks and ATR-FTIR spectroscopy.

Authors:  Afroditi Kapourani; Vasiliki Valkanioti; Konstantinos N Kontogiannopoulos; Panagiotis Barmpalexis
Journal:  Int J Pharm X       Date:  2020-12-08

Review 4.  Challenges in application of Raman spectroscopy to biology and materials.

Authors:  Nikki Kuhar; Sanchita Sil; Taru Verma; Siva Umapathy
Journal:  RSC Adv       Date:  2018-07-20       Impact factor: 4.036

5.  Studying the Impact of the Temperature and Sorbed Water during Microwave-Induced In Situ Amorphization: A Case Study of Celecoxib and Polyvinylpyrrolidone.

Authors:  Nele-Johanna Hempel; Matthias M Knopp; Korbinian Löbmann; Ragna Berthelsen
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

6.  The Influence of Drug-Polymer Solubility on Laser-Induced In Situ Drug Amorphization Using Photothermal Plasmonic Nanoparticles.

Authors:  Nele-Johanna Hempel; Padryk Merkl; Matthias Manne Knopp; Ragna Berthelsen; Alexandra Teleki; Georgios A Sotiriou; Korbinian Löbmann
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.